Polaryx Therapeutics, Inc. Common Stock

NASDAQ:PLYX

Biotechnology

Healthcare
$1.61 -0.87%

-$0.02 today

Market cap
$80.25M
Beta
0.00
P/E (TTM)
-16.7
EPS (TTM)
-$0.14
52W Low $2.01High $48.91

Volume 0.02M

Average 0.34M

PLYX Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Polaryx Therapeutics, Inc. Common StockNASDAQ: PLYX

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) declines year over year

Q1 FY2026 weighted avg shares (diluted) of 47.22M shares fell 75.1% year over year. Sequentially, it fell 0.3% from the prior quarter.

Context

  • Weighted avg shares (diluted) increased in 0 of the last 2 fiscal years.
  • FY2025 was the lowest annual figure in the 3 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
47.22M-0.3% QoQ
Last fiscal yearDec 2025
47.34M-75.0% YoY
LTMMar 2026
118.33M— YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-75.1%——
1 year-75.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
47.34M USD
Year-over-year change
-75.0%
2-year CAGR
-50.0%

Weighted Avg Shares (Diluted) vs competitors

How PLYX compares with its peers on the latest reported figures

  • PLYX's LTM Mar 2026 weighted avg shares (diluted) of 118.33M shares is the highest of the 8 companies compared; the peer median is 21.01M shares.
PLYX Competitors Peer median
Weighted Avg Shares (Diluted) for PLYX and competitors
Company Period LTM YoY 3-year CAGR
PLYXPolaryx Therapeutics, Inc. Common StockLTM Mar 2026118.33M ——
FHTXFoghorn Therapeutics Inc.LTM Mar 202664.63M +7.9%+14.8%
JBIOJade Biosciences, Inc.LTM Mar 202643.78M +3008.4%+255.3%
ANTXAN2 Therapeutics, Inc.LTM Mar 202631.18M +4.3%+25.4%
KLRSKalaris Therapeutics IncLTM Mar 202621.01M +341.4%+66.1%
LYELLyell Immunopharma, Inc.LTM Mar 202618.01M +34.2%+11.4%
CBIOCrescent Biopharma, Inc.LTM Mar 202617.74M -57.8%-41.7%
PTHSPelthos Therapeutics Inc.LTM Mar 20261.94M +227.5%+48.3%
Peer median (excluding PLYX) 21.01M+34.2%+25.4%

Competitors are the stored peer set for PLYX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue000
Cost of Revenue000
Gross Profit000
Gross Margin———
Research & Development2.77M2.81M6.27M
Selling, General & Admin1.01M1.54M1.56M
Operating Expenses3.78M4.35M7.82M
Depreciation & Amortization000
EBITDA(3.78M)(30.36M)(8.99M)
EBITDA Margin———
Operating Income(3.78M)(4.35M)(7.82M)
Operating Margin———
Interest Income000
Interest Expense000
Other Income / Expenses2K(26M)(1.16M)
Income Before Tax(3.78M)(30.36M)(8.99M)
Pre-Tax Margin———
Income Tax Expense000
Net Income(3.78M)(30.36M)(8.99M)
Net Margin———
EPS (Basic)(0.02)(0.16)(0.19)
EPS (Diluted)(0.02)(0.16)(0.19)
Weighted Avg Shares189.37M189.37M47.34M
Weighted Avg Shares (Diluted)189.37M189.37M47.34M

Polaryx Therapeutics, Inc. Common Stock

NASDAQ:PLYX

Intrinsic Alpha fair value

Locked

Current Price

$1.61

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.